This trial is active, not recruiting.

Condition diabetes mellitus
Treatment far infrared radiation
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date May 2006
End date February 2009
Trial size 2 participants
Trial identifier NCT00573456, GAAD-DM-CTP1


A study to determine the use of far infrared (FIR) radiation for treatment of diabetes.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
far infrared radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.

Primary Outcomes

The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes.
time frame: 2 years

Secondary Outcomes

The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure.
time frame: 2 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Persons with type 1 or type 2 diabetes Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes
Description Diabetes mellitus is a disease in which glucose is not sufficiently metabolized. This results in high glucose levels in blood and glucose in the urine. Cells can starve because glucose is not being metabolized. Both types of diabetes can cause dangerous complications, including blindness, heart and blood vessel disease, and kidney failure. A decrease in circulation may eventually require the amputation of limbs. We are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby improving the health of the patients.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..